. 2016; 33(4): 299-303 | DOI: 10.4274/tjh.2015.0271 | |||
Hiperkoagülabilite Durumları Olan Hastalarda Terapötik Uluslararası Düzeltme Oranına Ulaşmak için Gerekli Warfarin Doz ve SüresiPushpinderdeep Kahlon1, Shahzaib Nabi1, Adeel Arshad2, Absia Jabbar3, Ali Haythem41Wayne State University, Henry Ford Health System, Clinic of Internal Medicine, Detroit, USA2Weill Cornell University, Hamad Medical Corporation, Clinic of Internal Medicine, Doha, Qatar 3Nishtar Hospital, University of Health Science, Multan, Pakistan 4Wayne State University, Henry Ford Health System, Clinic of Hematology-Oncology, Detroit, USA Amaç: Bu çalışmanın amacı kontrollerle karşılaştırıldığında hiperkoagülabilite durumları olan hastalarda terapötik uluslararası düzeltme oranında (INR) 2 ile 3 aralığına ulaşmak için gerekli warfarin doz ve antikoagülan süresindeki farklılığı analiz etmektir. Bildiğimiz kadarıyla; bu farklılığı tarifleyen literatürdeki ilk çalışmadır. Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable ConditionsPushpinderdeep Kahlon1, Shahzaib Nabi1, Adeel Arshad2, Absia Jabbar3, Ali Haythem41Wayne State University, Henry Ford Health System, Clinic of Internal Medicine, Detroit, USA2Weill Cornell University, Hamad Medical Corporation, Clinic of Internal Medicine, Doha, Qatar 3Nishtar Hospital, University of Health Science, Multan, Pakistan 4Wayne State University, Henry Ford Health System, Clinic of Hematology-Oncology, Detroit, USA Objective: The purpose of this study was to analyze the difference in duration of anticoagulation and dose of warfarin required to reach a therapeutic international normalized ratio [(INR) of 2 to 3] in patients with hypercoagulable conditions as compared to controls. To our knowledge, this study is the first in the literature to delineate such a difference. Pushpinderdeep Kahlon, Shahzaib Nabi, Adeel Arshad, Absia Jabbar, Ali Haythem. Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions. . 2016; 33(4): 299-303 Sorumlu Yazar: Shahzaib Nabi, United States |
|